2-甲基-5-三氟甲基苯硼酸 | 947533-96-2

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-5-三氟甲基苯硼酸
• 英文名称: (2-methyl-5-(trifluoromethyl)phenyl)boronic acid
• 英文别名: 2-Methyl-5-(trifluoromethyl)phenylboronic acid；[2-methyl-5-(trifluoromethyl)phenyl]boronic acid
• CAS: 947533-96-2
• 化学式: C₈H₈BF₃O₂
• 分子量: 203.957
• InChiKey: WFARXIDYQNIXLI-UHFFFAOYSA-N

物化性质

• 沸点：
  287.0±50.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.69
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2931900090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  2-甲基-5-三氟甲基苯硼酸 生成 (rac)-((1s,3s)-3-Hydroxy-3-methylcyclobutyl)(6-(2-methyl-5-(trifluoromethyl)phenyl)-2-azaspiro[3.4]octan-2-yl)methanone
  参考文献：
  名称：

  CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS

  摘要：

  式(I)的化合物及其药用盐、同位素、N-氧化物、溶剂合物和立体异构体，包含它们的药物组合物，制备它们的方法以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、疾病和症状的方法，如与疼痛、精神障碍、神经障碍（包括但不限于抑郁症、重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合征和躁狂症）、癌症和眼部疾病相关的疾病状态、疾病和症状：其中R1、R3和L如本文所定义。

  公开号：

  US20220089538A1

文献信息

• Sulfonamides as Selective Na_V1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity
  作者：Russell F. Graceffa、Alessandro A. Boezio、Jessica Able、Steven Altmann、Loren M. Berry、Christiane Boezio、John R. Butler、Margaret Chu-Moyer、Melanie Cooke、Erin F. DiMauro、Thomas A. Dineen、Elma Feric Bojic、Robert S. Foti、Robert T. Fremeau、Angel Guzman-Perez、Hua Gao、Hakan Gunaydin、Hongbing Huang、Liyue Huang、Christopher Ilch、Michael Jarosh、Thomas Kornecook、Charles R. Kreiman、Daniel S. La、Joseph Ligutti、Benjamin C. Milgram、Min-Hwa Jasmine Lin、Isaac E. Marx、Hanh N. Nguyen、Emily A. Peterson、Gwen Rescourio、John Roberts、Laurie Schenkel、Roman Shimanovich、Brian A. Sparling、John Stellwagen、Kristin Taborn、Karina R. Vaida、Jean Wang、John Yeoman、Violeta Yu、Dawn Zhu、Bryan D. Moyer、Matthew M. Weiss

  DOI：10.1021/acs.jmedchem.6b01850

  日期：2017.7.27

  genetic validation, NaV1.7 has attracted significant interest as a target for the treatment of pain. We have previously reported on a number of structurally distinct bicyclic heteroarylsulfonamides as NaV1.7 inhibitors that demonstrate high levels of selectivity over other NaV isoforms. Herein, we report the discovery and optimization of a series of atropisomeric quinolinone sulfonamide inhibitors [Bicyclic

  由于其强大的遗传学验证，Na V 1.7作为治疗疼痛的靶标引起了人们的极大兴趣。我们以前曾报道过许多结构上不同的双环杂芳基磺酰胺盐，它们是Na V 1.7抑制剂，与其他Na V同工型相比，具有较高的选择性。在此，我们报告了一系列阻转异构的喹啉酮磺酰胺抑制剂[双环磺酰胺化合物作为钠通道抑制剂]的发现和优化及其制备方法。WO 2014201206， 2014]的Na V 1.7，这表明的Na纳摩尔抑制V 1.7和比其他钠通道亚型表现出高水平的选择性。在优化了包括PXR活化，CYP2C9抑制和CYP3A4 TDI在内的代谢和药代动力学特性后，将几种化合物推入了体内靶标参与和功效模型。在小鼠中进行测试时，化合物39（AM-0466）在组胺诱导的瘙痒性Na V 1.7依赖性模型（瘙痒）中以及在辣椒素诱导的痛觉伤害模型中均表现出强大的药效学活性，而在开腹中没有任何混淆作用现场活动。
• [EN] SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS<br/>[FR] 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR GLUN2B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018067786A1

  公开（公告）日：2018-04-12

  Substituted 1 H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  1-取代的1H-咪唑[4,5-b]吡啶-2(3H)-酮作为NR2B受体配体。这类化合物可用于NR2B受体调节以及用于治疗由NR2B受体活性介导的疾病状态、疾病和病况的药物组合物和方法。
• Biphenyl Cyclobutenone Photoelectrocyclizations
  作者：Changhang Dai、Xuchen Zhao、Changqing Song、Zach Schwartz、Jon D. Rainier

  DOI：10.1021/acs.joc.1c01809

  日期：2021.11.5

  In this work, we demonstrate that readily available conjugated bis-aryl cyclobutenones undergo photoelectrocyclization reactions to give the corresponding dihydrophenanthrene cyclobutanones when exposed to 350 nm light, TFA, and TMSCl. We have also found that cyclobutenone electrocyclizations and cycloreversions are in equilibrium.

  在这项工作中，我们证明了容易获得的共轭双芳基环丁烯酮在暴露于 350 nm 光、TFA 和 TMSCl 时会发生光电环化反应以产生相应的二氢菲环丁酮。我们还发现环丁烯酮的电环化和环化反应处于平衡状态。
• Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer
  申请人：THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING

  公开号：US20160002175A1

  公开（公告）日：2016-01-07

  A compound of formula (I), or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.

  公式（I）的化合物，或其药学上可接受的盐。该化合物可用于治疗癌症或其他可能从MTH1抑制中受益的疾病。
• Discovery of a Novel Glucagon Receptor Antagonist <i>N</i>-[(4-{(1<i>S</i>)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1<i>H</i>-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes
  作者：Yusheng Xiong、Jian Guo、Mari R. Candelore、Rui Liang、Corey Miller、Qing Dallas-Yang、Guoqiang Jiang、Peggy E. McCann、Sajjad A. Qureshi、Xinchun Tong、Shiyao Sherrie Xu、Jackie Shang、Stella H. Vincent、Laurie M. Tota、Michael J. Wright、Xiaodong Yang、Bei B. Zhang、James R. Tata、Emma R. Parmee

  DOI：10.1021/jm300579z

  日期：2012.7.12

  A potent, selective glucagon receptor antagonist 9m, N-[(4-(1S)-1-[3-(3,5-dichlorophenyl) -5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)-carbonyl]-beta-alanine, was discovered by optimization of a previously identified lead. Compound 9m is a reversible and competitive antagonist with high binding affinity (IC50 of 6.6 nM) and functional cAMP activity (IC50 of 15.7 nM). It is selective for glucagon receptor relative to other family B GPCRs, showing IC50 values of 1020 nM for GIPR, 9200 nM for PAC1, and >10000 nM for GLP-1R, VPAC1, and VPAC2. Compound 9m blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It also lowered ambient glucose levels in both acute and chronic mouse models: in hGCGR ob/ob mice it reduced glucose (AUC 0-6 h) by 32% and 39% at 3 and 10 mpk single doses, respectively. In hGCGR mice on a high fat diet, compound 9m at 3, and 10 mpk po in feed lowered blood glucose levels by 89% and 94% at day 10, respectively, relative to the difference between the vehicle control and lean hGCGR mice. On the basis of its favorable biological and DMPK properties, compound 9m (MK-0893) was selected for further preclinical and clinical evaluations.